SCHEMBL20178665

SCHEMBL20178665

CCOC(=O)c1ccc2c(c1)CCCN2CC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 2/20 0.56
SRD5A2 P31213 1/20 0.56
ALDH1A1 P00352 3/20 0.50
LMNA P02545 2/20 0.50
HPGD P15428 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HRH3 Q9Y5N1 1/20 0.46
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
MAPT P10636 5/20 0.46
ALOX5 P09917 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
HDAC3 O15379 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178648 0.92 SRD5A1 (0.58) SRD5A1SRD5A2ALDH1A1LMNAHPGD
SCHEMBL20178706 0.90 SRD5A1 (0.47) SRD5A1SRD5A2ALDH1A1LMNAHPGD
SCHEMBL20119320 0.85 SRD5A1 (0.57) SRD5A1SRD5A2ALDH1A1LMNAHPGD
SCHEMBL20178649 0.85 ALDH1A1 (0.52) ALDH1A1LMNAHRH3CHRM2CHRM4
SCHEMBL1310717 0.85 HDAC1 (0.49) ALDH1A1LMNAHPGDNPSR1HRH3
SCHEMBL18593240 0.83 GAA (0.54) ALDH1A1LMNAHPGDHRH3CHRM2
SCHEMBL20173809 0.82 SRD5A1 (0.54) SRD5A1SRD5A2ALDH1A1LMNAHPGD
SCHEMBL20119318 0.80 SRD5A1 (0.59) SRD5A1SRD5A2ALDH1A1LMNAMAPT
SCHEMBL10473419 0.79 HRH3 (0.48) ALDH1A1LMNAHPGDNPSR1HRH3
SCHEMBL1311927 0.79 HDAC1 (0.53) ALDH1A1HRH3MAPTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 SRD5A1 184/4885SRD5A2 253/4885ALDH1A1 2185/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 SRD5A1 184/4885SRD5A2 253/4885ALDH1A1 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.